- In the News
- Welcome to PDSA
News from the 2016 ASH Meeting
The 58th Annual Meeting of the American Society of Hematology is being held from December 3-6 in San Diego, CA and representatives from PDSA are there representing the ITP community.
Click on the link below for the latest news and information from the ASH meeting.
NORD Ready to Address New Challenges Based on Election Results
The following statement was issued by Peter L. Saltonstall, President and CEO of the National Organization for Rare Disorders (NORD), following the results of the recent U.S. election.
“Many of us were surprised by the outcome of the presidential election last week. The pollsters and the pundits were predicting a different outcome. But the long election season has ended and we have a new President, a new Congress, and a series of new challenges for NORD and the rare disease community.
Healthcare is one of the top priorities of President-elect Trump. At the top of the agenda is his pledge to replace the Affordable Care Act. With both houses of Congress having a Republican majority, the incoming President is likely to have support for his goals. The new President also has made comments about the drug development process and about the drug approval process at FDA and about other issues that may…
AARDA Salutes PDSA and Other Autoimmune Heros
"AARDA’s #AutoimmuneHeroes campaign recognizes the work of individuals and organizations that have advanced the autoimmune disease agenda in the areas of research, patient safety, advocacy, public education and awareness, service and volunteerism, among others."
- From AARDA Press Release
Zika Virus and Plasma Protein Therapies
"Recent ZIKV infection has also been associated with an increased incidence of Guillain–Barré syndrome (GBS). PPTA is aware that persons who use plasma protein therapies are understandably concerned about whether these therapies remain safe with respect to the ZIKV. ZIKV is a Flavivirus that is primarily transmitted by infected Aedes mosquitoes (5), however, transmission may also occur by sexual contact, from a pregnant woman to her unborn child during pregnancy or during birth, or by transfusion of infected blood."
- From PPTA Press Release
Low-level laser therapy may improve treatment of dangerous bleeding disorder
"A low-intensity type of laser treatment may offer a non-invasive, drug-free treatment for thrombocytopenia – a potentially life-threatening shortage of the blood cells called platelets that are essential to blood clotting. In their paper appearing in Science Translational Medicine, a research team from the Wellman Center for Photomedicine at Massachusetts General Hospital (MGH) reports that low-level laser therapy increased the generation of platelets from precursor cells called megakaryocytes (MKs) and had the same effect in several mouse models of the condition. They also identified the probable mechanism underlying this effect."
- From Mass. General Hospital press release
"Making the world of ITP a more manageable place to be"
The Platelet Disorder Support Association is dedicated to enhancing the lives of people with immune thrombocytopenia (ITP) and other platelet disorders through:
Education • Advocacy • Research • Support
Comprehensive information on conventional therapies usually prescribed for ITP as well as therapies outside of the usual medical mainstream that some patients with ITP have used successfully.
Advocacy helps build awareness and support for ITP and other platelet disorders. Everyone interested in having more people know about ITP, having greater access to treatment, and getting more funding ITP and related diseases can help.
ITP Conference DVDs, free booklets and pamphlets, diet and lifestyle information, PDSA newsletters, journal articles and abstracts, PDSA E-News.